FULCRUM THERAPEUTICS INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANIncentive Stock Option Agreement • May 1st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
FULCRUM THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANNonstatutory Stock Option Agreement • May 1st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
RIGHT OF REFERENCE AND LICENSE AGREEMENTRight of Reference and License Agreement • May 1st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS RIGHT OF REFERENCE AND LICENSE AGREEMENT (this “Agreement”), dated as of February 8, 2019 (the “Effective Date”), is made and entered into by and between GlaxoSmithKline Intellectual Property (No. 2) Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GIP2”), GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at 1250 S. Collegeville Road, Collegeville, PA 19426-0989 (“GSK LLC”) and Glaxo Group Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GGL”) (GIP2, GSK LLC and GGL are collectively referred to herein as “GSK”), and Fulcrum Therapeutics, Inc., a Delaware corporation having a place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“Fulcrum”). GSK and Fulcrum may be referred to herein individually as a “Party” and collective
FULCRUM THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANRestricted Stock Agreement • May 1st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 2016, between Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”).
FULCRUM THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 24, 2018Adoption Agreement • May 1st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of August 24, 2018, by and among Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
